New York, May 21, 2026, 10:05 EDT
- PROCEPT BioRobotics shares were up 0.6% at $28.29 in early trading, with latest available data showing a session range of $28.07 to $28.29.
- Nasdaq’s regular session was open; the exchange lists Memorial Day, May 25, as the next 2026 U.S. market closure.
- Investors are weighing stronger Aquablation clinical support against PROCEPT’s losses and execution risk.
PROCEPT BioRobotics shares rose early Thursday, holding up better than parts of the medical-device tape as Wall Street opened lower on renewed oil and Middle East worries. PRCT was last at $28.29, up 18 cents, while Reuters reported that the Dow, S&P 500 and Nasdaq all opened lower.
That small move matters for a stock still trying to recover credibility after a bruising guidance reset earlier this year. PROCEPT, valued at about $1.60 billion in the latest available market data, needs to show that demand for its Aquablation systems can turn into steadier procedure growth, consumable sales and a narrower cash burn.
The current company hook is clinical, not a fresh earnings release. PROCEPT’s most recent posted press release, dated May 14, said the American Urological Association strengthened its recommendation for Aquablation therapy, a robot-assisted waterjet treatment, for men with lower urinary tract symptoms tied to benign prostatic hyperplasia, or BPH, an enlarged prostate condition. The update covered prostate volumes of 30–80 mL and recognized use in larger prostates of 80–150 mL.
Chief Executive Larry Wood said the guideline change reflected “growing adoption” in practice. Ricardo Gonzalez, MD, of Houston Methodist, said the guidance now tells clinicians they should “offer Aquablation therapy.” PROCEPT BioRobotics Corp
The stock’s test is whether that support shows up in numbers. PROCEPT reported first-quarter revenue of $83.1 million, up 20% from a year earlier, and about 12,200 U.S. procedures, up roughly 30%. It also sold 49 U.S. Hydros systems, including two replacement systems, and reaffirmed 2026 revenue guidance of $390 million to $410 million.
Wood said first-quarter revenue was helped by “strong U.S. system sales and improved pricing,” but also flagged “near-term disruption” from a commercial realignment. The company posted a net loss of $31.6 million, wider than $24.7 million a year earlier, and an adjusted EBITDA loss of $18.1 million; adjusted EBITDA means earnings before interest, taxes, depreciation and amortization, with some items such as stock-based compensation excluded. PROCEPT BioRobotics Corp
The peer backdrop was mixed but mostly soft. The iShares U.S. Medical Devices ETF fell 1.7%, Intuitive Surgical dropped 2.6% and Boston Scientific slipped 0.2% in the latest available early trade data, putting PRCT’s modest rise in contrast with larger device names.
PROCEPT is not trying to match Intuitive’s broad surgical robotics platform. Its pitch is narrower: persuade hospitals and urologists to standardize a robotic therapy for BPH, then earn recurring revenue from procedures and handpieces.
But the risk is still execution. First-quarter handpiece sales were about 95% of U.S. procedures, and the full-year outlook assumes U.S. procedure growth of 39% to 48%. If hospital capital spending slows, the sales-force changes drag on longer, or handpiece demand fails to line up with procedures, the guidance range could look harder to defend.
That worry is not new. After the fourth-quarter reset, Investor’s Business Daily quoted Leerink Partners analyst Mike Kratky calling the print “especially disappointing,” even as he kept an outperform rating and cut his price target to $30 from $55. Investors
The next scheduled management appearance is the William Blair Growth Stock Conference on June 2, followed by the Truist Med-Tech Conference on June 16. For PRCT, those meetings may matter less for the slides than for whether management can keep investors focused on procedure growth rather than last quarter’s disruption.
